Video

Nisha Thacker: The Western Diet and Pediatric IBD

Author(s):

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.

Diet has always been a crucial aspect of treating inflammatory bowel disease (IBD).

A diet that is high in fats and fried foods can increase the risk of developing IBD and exacerbate symptoms.

While much of the research has centered on adults with IBD, there is now research that shows pediatric patients are more likely to develop IBD if they develop a “Western diet” that is high in fried, fatty foods and lacks a lot of fruits and vegetables.

In an abstract presented during the 2023 Digestive Disease Week (DDW) in Chicago, Nisha Thacker, University of Newcastle, presented data showing that the Western diet does result in a high risk of developing IBD for pediatric patients.

In an interview with HCPLive®, Thacker talked about why it is important for pregnant women to have a cleaner diet that will reduce the risk of the child developing IBD.

In the study, Thacker, who is a PhD student, led a team who screened 4763 studies involving 4.6 million participants. They found a lower risk of pediatric IBD for those with regular or higher vegetable intake and a higher risk of pediatric IBD for those who have regular intakes of sugary beverages and/or candies.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.